🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Gastroesophageal Junction Adenocarcinoma
Clinical trial register · China

Gastroesophageal Junction Adenocarcinoma Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 17 Harbin 10 Guangzhou 8 Zhengzhou 8 Xiamen 7
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Nanfang Hospital, Southern Medical University2 AstraZeneca2 West China Hospital2 Tianjin Medical University Cancer Institute and Hospital2 RemeGen Co., Ltd.2
Site location
Beijing17 Harbin10 Guangzhou8 Zhengzhou8 Xiamen7
All 34 locations
Target enrolment
to

Gastroesophageal Junction Adenocarcinoma trials in China

38 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
ctDNA-MRD Monitoring After Neoadjuvant Therapy in Gastric Cancer With pCR or MPR
NCT07799649Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
The First Affiliated Hospital with Nanjing Medical University
Observational
150
Nanjing
2026-09
Not yet open
Sacituzumab Tirumotecan (Sac-TMT/SKB264) Plus Tagitanlimab (KL-A167) in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma
NCT07701681ESCC, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Squamous Cell Carcinoma (ESCC)
DrugsTagitanlimab·Sacituzumab tirumotecan
Sun Yat-sen University
Phase 2
75
Guangzhou
2026-08-31
Not yet open
Mannatide Combined With CAPOX and Tislelizumab for Advanced Gastric Cancer.
NCT07655661Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
DrugsOxaliplatin·Capecitabine·Tislelizumab
Ming Liu
Phase 2
52
Chengdu
2026-07-01
Recruiting
Chemoradiotherapy and SHR-1701 in Patients With Unresectable Gastric Cancer
NCT07689851Gastric Cancer (GC), Gastroesophageal Junction Adenocarcinoma
DrugSHR-1701
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
60
Shenzhen, Taiyuan, Beijing
2026-07-01
Not yet open
Zanidatamab Combined With Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positive (IHC 3+ or IHC 2+) Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a Phase II Open-Label Study
NCT07685704Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, HER2-positive Gastric Cancer
DrugsZanidatamab·Tegafur Gimeracil Oteracil·Oxaliplatin·Capecitabine
Zhifeng Zhao, PhD
Phase 2
46
Xi'an
2026-07
Not yet open
SKB315 in Combination Therapy in Patients With Advanced or Metastatic GC/ GEJ Adenocarcinoma
NCT07609667Gastroesophageal Junction Adenocarcinoma
DrugsSKB315·Capecitabine·Tislelizumab
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 2
80
Beijing
2026-06-30
Not yet open
Adaptive Adjuvant Therapy After Neoadjuvant Therapy and Gastrectomy for Gastric or Gastroesophageal Junction Adenocarcinoma
NCT07603349Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Nanfang Hospital, Southern Medical University
Phase 2/3
405
Guangzhou
2026-06
Recruiting
A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment
NCT07518147Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
DrugsBL-M05D1·Irinotecan Hydrochloride·Paclitaxel
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
438
Beijing
2026-05-15
Active, closed
Iparomlimab and Tuvonralimab Injection (QL1706) Combined With DOS as Neoadjuvant Therapy for Locally Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction
NCT07776639Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma
DrugsTegafur Gimeracil Oteracil·Iparomlimab and Tuvonralimab·Oxaliplatin·Paclitaxel
Yongxu Jia
Phase 2
34
Zhengzhou
2026-05-10
Recruiting
IBI343 in Combination With Sintilimab and SOX Regimen for Perioperative Treatment of Resectable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
NCT07483567CLDN18.2 Positive, Primary Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Innovent Biologics (Suzhou) Co. Ltd.
Phase 2
90
Beijing
2026-04-17
Recruiting
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
NCT07431281Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer
DrugsSonesitatug vedotin·Zolbetuximab·Rilvegostomig·Leucovorin
AstraZeneca
Phase 3
2,130
Beijing, Changde, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin
2026-02-03
Recruiting
SHR-1701 + Rivoceranib (± SHR-2554) in Advanced GC After First-Line Immunotherapy Failure
NCT07311408Gastric Cancer (GC), Gastroesophageal Junction Adenocarcinoma
DrugsRivoceranib·SHR-1701
Jingdong Zhang
Phase 2
40
Shenyang
2026-01-01
Recruiting
Hypofractionated Radiotherapy Plus Immunochemotherapy for Neoadjuvant Treatment of Gastroesophageal Junction Adenocarcinoma
NCT07182565Gastroesophageal Junction Adenocarcinoma, Hypofractionated Radiotherapy
DrugTS-1)
West China Hospital
Phase 1/2
84
Xiamen, Chengdu
2025-11-18
Recruiting
TAIC FOLFOX for Locally Advanced G/GEJA
NCT07655024Gastric Cancer (Diagnosis), Gastroesophageal Junction Adenocarcinoma
DrugFolfox
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Phase 2
31
Beijing
2025-11-01
Recruiting
To Evaluate the Efficacy of CT041 in Sequential Treatment After First-line Treatment of Advanced Gastric/Esophagogastric Junction Adenocarcinoma
NCT07179484Gastroesophageal Junction Adenocarcinoma
DrugCT041 autologous CAR T-cell
Beijing GoBroad Hospital
Observational
20
Beijing
2025-10-22
Recruiting
A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-positive Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction Adenocarcinoma
NCT07152405Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
DrugBL-M07D1
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
490
Harbin, Shanghai
2025-09-24
Recruiting
Hypofractionated Radiotherapy Combined With Immunochemotherapy for Conversion Treatment of Gastroesophageal Junction Adenocarcinoma
NCT07072351Gastroesophageal Junction Adenocarcinoma, Hypofractionated Radiotherapy, Immunotherapy, Chemotherapy
West China Hospital
Phase 1/2
88
Xiamen, Chengdu
2025-09-15
Recruiting
Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma
NCT07102901Advanced Gastric Cancer, Metastatic Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
DrugsSHR-A1904·SHR-1701·Zeprumetostat·Trastuzumab Rezetecan
Jiangsu HengRui Medicine Co., Ltd.
Phase 2
351
Harbin, Zhengzhou
2025-09-05
Not yet open
The Efficacy and Safety of Iparomlimab/Tuvonralimab (Anti PD-1/CTLA-4) Combined With Albumin-bound Paclitaxel in Second-line Treatment of Patients With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
NCT07139587Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
DrugsAlbumin-Bound Paclitaxel·Iparomlimab and Tuvonralimab
Qingxia Li
Not applicable
30
Shijiazhuang
2025-09
Recruiting
A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
NCT07043400Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
DrugsLeucovorin·Oxaliplatin·Capecitabine·Cisplatin
BeOne Medicines
Phase 3
351
Hefei, Beijing, Xiamen, Anyang, Zhengzhou, Nanjing, Ganzhou, Shenyang
2025-08-27
Not yet open
Postoperative Adjuvant Therapy for CT041 Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma Patients
NCT06857786Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma
Peking University
Phase 1
48
Beijing, Nanjing
2025-03-10
Recruiting
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
NCT06764875HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
DrugsRilvegostomig·Trastuzumab deruxtecan·Trastuzumab·Oxaliplatin
AstraZeneca
Phase 3
840
Anyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou
2025-03-01
Recruiting
BC001 in Combination with Sintilimab and XELOX in the Treatment of HER-2 Negative Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma.
NCT06773312Advanced or Metastatic Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.
Phase 1
80
Beijing
2025-02-28
Active, closed
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
NCT06628310Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
DrugsBudigalimab·Telisotuzumab Adizutecan·Leucovorin·Oxaliplatin
AbbVie
Phase 2
185
Beijing, Langfang, Harbin, Wuhan, Hangzhou
2024-12-13
Active, closed
Sintilimab in Combination with Chemotherapy ± Local Treatment for Om-G/GEJ
NCT06739161Gastroesophageal Junction Adenocarcinoma
Jiangsu Cancer Institute & Hospital
Phase 2
120
Nanjing
2024-12-02
Not yet open
A Study of Anti-PD-1 and LAG-3 Bispecific Antibody(AK129) Combined With Chemotherapy With or Without Cadonilimab in the First-line Treatment of Unresectable Locally Advanced or Metastatic G/ GEJ Adenocarcinoma
NCT06586294Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Akeso
Phase 1/2
294
Hanzhou
2024-09-10
Recruiting
Disitamab Vedotin Combined With Tislelizumab and Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Cancer With HER2 Overexpression
NCT06560528Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2
40
Tianjin
2024-09-01
Recruiting
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
NCT06324357Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
DrugsZongertinib·Zanidatamab·MFOLFOX6·Trastuzumab emtansine
Boehringer Ingelheim
Phase 1/2
768
Changchun, Hangzhou, Harbin, Nanjing, Shanghai, Tianjin, Zhengzhou
2024-06-28
Not yet open
Conversion Therapy of Sintilimab in Combination With Fruquintinib and Chemotherapy Versus Sintilimab and Chemotherpay in Stage IV Gastric Cancer
NCT06454435Gastric Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
DrugsTegafur Gimeracil Oteracil·Nab-paclitaxel·Tislelizumab
Tianjin Medical University Cancer Institute and Hospital
Phase 2
158
Tianjin
2024-06
Recruiting
AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer
NCT06196697Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Harbin Medical University
Phase 2
50
Harbin
2024-04-10
Recruiting
DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy
NCT06221748Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
DrugsDisitamab Vedotin·Cadonilimab·Paclitaxel
RemeGen Co., Ltd.
Phase 2/3
90
Beijing, Xiamen, Harbin, Zhengzhou, Wuhan, Changsha, Xuzhou, Jinan
2024-02-22
Active, closed
ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ Adenocarcinoma
NCT06206733Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma
DrugsASKB589·Oxaliplatin·Capecitabine·Tislelizumab
AskGene Pharma, Inc.
Phase 3
780
Beijing
2024-01-25
Recruiting
Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.
NCT06155383Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
DrugsDisitamab Vedotin·Oxaliplatin·Capecitabine·Tislelizumab
RemeGen Co., Ltd.
Phase 2
90
Beijing, Fuzhou, Kunming, Xiamen, Wuwei, Guangzhou, Harbin, Zhengzhou
2023-11-27
Active, closed
A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)
NCT05002127Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma
DrugsEvorpacept·Ramucirumab·Trastuzumab·Paclitaxel
ALX Oncology Inc.
Phase 2/3
127
2022-01-15
Recruiting
Relationship Between Perioperative Treatment Efficacy and The Tumor Microenvironment for Locally Advanced Resectable Gastric Cancer.
NCT04850729Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Nanfang Hospital, Southern Medical University
Observational
169
Guangzhou
2021-05-25
Active, closed
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
NCT04704934Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
DrugsRamucirumab·Trastuzumab deruxtecan·Paclitaxel
Daiichi Sankyo
Phase 3
490
Heifi, Fuzhou, Xiamen, Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Changshan
2021-05-21
Active, closed
Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection
NCT04581473Gastric Adenocarcinoma, Pancreatic Cancer, Gastroesophageal Junction Adenocarcinoma
DrugsCT041 autologous CAR T-cell·Apatinib·Irinotecan
CARsgen Therapeutics Co., Ltd.
Phase 1/2
192
Hefei, Beijing, Fuzhou, Shenzhen, Harbin, Zhengzhou, Wuhan, Nanjing
2020-10-23
Active, closed
Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)
NCT04152499Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma
DrugSacituzumab tirumotecan
Klus Pharma Inc.
Phase 1/2
1,410
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou
2020-02-28
Rows per page Showing 1–38 of 38
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/condition/gastroesophageal-junction-adenocarcinoma

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 38 of those studies listing the condition Gastroesophageal Junction Adenocarcinoma.

How many Gastroesophageal Junction Adenocarcinoma trials are recruiting in China?

20 of the 38 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 10 have not yet opened recruitment, 8 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Gastroesophageal Junction Adenocarcinoma), 38 studies
PhaseStudiesRecruitingShare
Phase 216842.1%
Phase 37518.4%
Phase 1/26315.8%
Observational327.9%
Phase 2/3317.9%
Phase 1215.3%
Not applicable102.6%

Most active sponsors

Lead sponsors with the most studies (Gastroesophageal Junction Adenocarcinoma)
Lead sponsorStudiesRecruiting
AstraZeneca22
Nanfang Hospital, Southern Medical University21
RemeGen Co., Ltd.22
Sichuan Baili Pharmaceutical Co., Ltd.22
Tianjin Medical University Cancer Institute and Hospital21
West China Hospital22
AbbVie10
Akeso10
ALX Oncology Inc.10
AskGene Pharma, Inc.10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.